Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2017

Study Completion Date

December 31, 2017

Conditions
Multiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary Progressive
Interventions
DRUG

ibudilast

Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.

DRUG

Placebo oral capsule

Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.

Trial Locations (28)

10021

Cornell Medical College, New York

10032

Columbia University Medical Center, New York

10467

Montefiore Medical Center, The Bronx

11794

University at Stony Brook, The State University of New York, Stony Brook

13210

University at Upstate, The State University of New York, Syracuse

14260

University at Buffalo, The State University of New York, Buffalo

14627

University of Rochester, Rochester

15261

University of Pittsburgh, Pittsburgh

22904

University of Virginia Charlottesville, Charlottesville

30322

Emory University, Atlanta

33136

University of Miami Miller School of Medicine, Miami

35294

University of Alabama at Birmingham, Birmingham

37235

Vanderbilt University, Nashville

43210

Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

45267

University of Cincinnati, Department of Neurology, Cincinnati

60208

Northwestern University, Evanston

63110

Washington University School of Medicine in St Louis, St Louis

66160

University of Kansas Medical Center, Kansas City

75390

University of Texas Southwestern Medical Center, Dallas

80045

University of Colorado Denver, Denver

84112

University of Utah, Salt Lake City

90095

University of California Los Angeles, Los Angeles

95817

University of California Davis, Davis

97239

Oregon Health and Science University, Portland

98122

Swedish Medical Center - Seattle, Seattle

02114

Massachusetts General Hospital, Boston

02445

Brigham and Women's Hospital, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

National Multiple Sclerosis Society

OTHER

lead

MediciNova

INDUSTRY

NCT01982942 - Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter